STAA - STAAR Surgical Company
After hours:
| Previous close | 59.79 |
| Open | 60.22 |
| Bid | 0.00 x 900 |
| Ask | 0.00 x 900 |
| Day's range | 57.62 - 60.49 |
| 52-week range | 46.36 - 112.27 |
| Volume | |
| Avg. volume | 572,619 |
| Market cap | 2.803B |
| Beta (5Y monthly) | 1.23 |
| PE ratio (TTM) | 89.23 |
| EPS (TTM) | 0.65 |
| Earnings date | 08 Aug 2023 - 14 Aug 2023 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 78.78 |
Simply Wall St.STAAR Surgical Company (NASDAQ:STAA) Stock's Been Sliding But Fundamentals Look Decent: Will The Market Correct The Share Price In The Future?
It is hard to get excited after looking at STAAR Surgical's (NASDAQ:STAA) recent performance, when its stock has...
Motley Fool2 Stocks With Unstoppable Growth Potential for the Next Decade
When a business is making headway in a massive and uncontested global market, shareholders reap the benefits. The result could well be a run of wild growth over the next few years. Align Technology's (NASDAQ: ALGN) business model is simple: It sells its Invisalign tooth straighteners to dentists and orthodontists, who use its scanning and 3D modeling devices to adapt the straighteners to fit their patients -- thus eliminating the need to get traditional braces.
- Simply Wall St.
STAAR Surgical (NASDAQ:STAA) Shareholders Will Want The ROCE Trajectory To Continue
If we want to find a stock that could multiply over the long term, what are the underlying trends we should look for...
Business WireEVO ICL Sponsors Jonas Brothers’ The Tour
LAKE FOREST, Calif., May 04, 2023--EVO ICL, the vision correction procedure that works in harmony with your natural eye, provides sharp, clear vision day or night and does not cause contact lens induced dry eye or dry eye syndrome, announced today sponsorship of the Jonas Brothers’ The Tour in North America, which begins August 12. Collaboration with the group will also include a new EVO advertising campaign slated for launch in the fall of 2023. The campaign will help drive education and awaren
ZacksStaar Surgical (STAA) Beats Q1 Earnings and Revenue Estimates
Staar Surgical (STAA) delivered earnings and revenue surprises of 63.64% and 10.82%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Business WireSTAAR Surgical Reports First Quarter 2023 Results
LAKE FOREST, Calif., May 03, 2023--STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of implantable lenses for the eye, today reported financial results for the first quarter ended March 31, 2023.
ZacksCardinal Health (CAH) Reports Next Week: Wall Street Expects Earnings Growth
Cardinal (CAH) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
ZacksEarnings Preview: Staar Surgical (STAA) Q1 Earnings Expected to Decline
Staar Surgical (STAA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- Simply Wall St.
Should You Think About Buying STAAR Surgical Company (NASDAQ:STAA) Now?
STAAR Surgical Company ( NASDAQ:STAA ), is not the largest company out there, but it led the NASDAQGM gainers with a...
Business WireSTAAR Surgical to Report First Quarter Results on May 3, 2023
LAKE FOREST, Calif., April 19, 2023--STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of implantable lenses for the eye, today announced that it will release financial results for the first quarter ended March 31, 2023 on Wednesday, May 3, 2023 after the market close.
- Simply Wall St.
STAAR Surgical's (NASDAQ:STAA) investors will be pleased with their incredible 346% return over the last five years
Long term investing can be life changing when you buy and hold the truly great businesses. And we've seen some truly...
ZacksStaar Surgical (STAA) Gains As Market Dips: What You Should Know
Staar Surgical (STAA) closed at $62.99 in the latest trading session, marking a +0.24% move from the prior day.
ZacksStaar Surgical (STAA) Stock Sinks As Market Gains: What You Should Know
Staar Surgical (STAA) closed the most recent trading day at $61.70, moving -0.11% from the previous trading session.
Business WireSTAAR Surgical Names Warren Foust Chief Operating Officer; Magda Michna, Ph.D., Chief Clinical, Regulatory and Medical Affairs Officer
LAKE FOREST, Calif., March 29, 2023--STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of implantable lenses for the eye, today announced Warren Foust has been named Chief Operating Officer and Magda Michna, Ph.D., has been named Chief Clinical, Regulatory and Medical Affairs Officer. Both positions will report to STAAR Surgical’s President and CEO, Tom Frinzi.
ZacksStaar Surgical (STAA) Outpaces Stock Market Gains: What You Should Know
Staar Surgical (STAA) closed the most recent trading day at $63.48, moving +1.6% from the previous trading session.
ZacksStaar Surgical (STAA) Dips More Than Broader Markets: What You Should Know
Staar Surgical (STAA) closed the most recent trading day at $61.24, moving -1.65% from the previous trading session.
ZacksImplied Volatility Surging for STAAR Surgical (STAA) Stock Options
Investors need to pay close attention to STAAR Surgical (STAA) stock based on the movements in the options market lately.
- Simply Wall St.
Calculating The Fair Value Of STAAR Surgical Company (NASDAQ:STAA)
Key Insights Using the 2 Stage Free Cash Flow to Equity, STAAR Surgical fair value estimate is US$64.35 With US$58.39...
- Simply Wall St.
STAAR Surgical Full Year 2022 Earnings: EPS: US$0.81 (vs US$0.52 in FY 2021)
STAAR Surgical ( NASDAQ:STAA ) Full Year 2022 Results Key Financial Results Revenue: US$284.4m (up 23% from FY 2021...
ZacksStaar Surgical (STAA) Lags Q4 Earnings and Revenue Estimates
Staar Surgical (STAA) delivered earnings and revenue surprises of -6.67% and 0.50%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Business WireSTAAR Surgical Reports Fourth Quarter and Fiscal Year 2022 Results
LAKE FOREST, Calif., February 21, 2023--STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of implantable lenses for the eye, today reported financial results for the fourth quarter and fiscal year ended December 30, 2022.
- Business Wire
STAAR Surgical to Report Fourth Quarter and Fiscal Year Results on February 21, 2023
LAKE FOREST, Calif., February 07, 2023--STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of implantable lenses and companion delivery systems for the eye, today announced that it will release financial results for the fourth quarter and fiscal year ended December 30, 2022, on Tuesday, February 21, 2023 after the market close.
ZacksSTAAR Surgical (STAA) to Report Q4 Earnings: What's in Store?
Strong growth in EVO ICL units led by increased market adoption is likely to have driven STAAR Surgical's (STAA) Q4 revenues.
ZacksSTAAR Surgical Company (STAA) Is a Trending Stock: Facts to Know Before Betting on It
Zacks.com users have recently been watching Staar Surgical (STAA) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Business WireActress and Beauty Entrepreneur Peyton List Sets Her Sights on 2023 with Upgraded Vision from Life-Changing EVO ICL Lenses
LAKE FOREST, Calif., January 11, 2023--STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of implantable lenses, today announced a partnership with actress and beauty entrepreneur, Peyton List, to further its mission of bringing EVO Implantable Collamer® Lenses (EVO) to the millions of Americans who suffer from myopia or nearsightedness. EVO is an FDA-approved vision correction lens designed for the correction/reduction of myopia with or without astigmatism. In
